Bengaluru-based medical technology startup Ayati Devices has raised Rs 15 crore ($1.5 million) in a Pre-Series A funding round led by Inflexor Ventures. 

The funds will be used to accelerate commercialisation, expand its presence in domestic and international markets, strengthen manufacturing capabilities, and increase investments in research and artificial intelligence.

Founded in 2019 by Nishant Kathpal, Ayati Devices focuses on diagnostic technologies for diabetic foot complications and peripheral vascular disease. The startup was incubated at IIT Bombay’s Society for Innovation and Entrepreneurship (SINE) and has built a portfolio of portable, point-of-care diagnostic devices aimed at making early screening accessible beyond tertiary hospitals.

Its product portfolio covers multiple stages of diabetic foot assessment. Vibrasense measures vibration perception threshold to identify large-fibre peripheral neuropathy, while Vibrasense+T adds warm and cold perception testing. 

Vasosense is designed for peripheral artery disease screening, while Angiocam enables real-time tissue perfusion imaging. The company also offers the PODIA Trolley, a pay-per-test screening model designed to reduce the upfront investment required for healthcare providers. Ayati’s current platform brings together assessments across neuropathy, blood flow, microcirculation and plantar pressure.

Ayati claims to have been deployed across 30 countries, with more than 10,000 devices deployed and clinical deployments across leading healthcare institutions. Its website currently reports that its solutions have enabled more than 1 million screenings, with the company working with partners across India and international markets.

The company’s flagship Vibrasense has also undergone clinical evaluation. A study involving 562 people with type 2 diabetes compared Vibrasense-based vibration perception threshold testing with conventional biothesiometry and nerve conduction studies for screening diabetic peripheral neuropathy.